financetom
Business
financetom
/
Business
/
Amgen's drug meets main goal in late-stage study for immune-system related condition
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Amgen's drug meets main goal in late-stage study for immune-system related condition
Jun 5, 2024 6:39 AM

June 5 (Reuters) - Amgen ( AMGN ) said on Wednesday its

drug to treat patients with an immune-system related condition

has met the main goal of a late-stage study.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Assembly Biosciences Doses First Subject in Phase 1a Trial of Hepatitis Delta Virus Therapy Candidate; Shares Up
Assembly Biosciences Doses First Subject in Phase 1a Trial of Hepatitis Delta Virus Therapy Candidate; Shares Up
Feb 26, 2025
10:22 AM EST, 02/26/2025 (MT Newswires) -- Assembly Biosciences ( ASMB ) shares were higher Wednesday morning after the company said that a first subject has been dosed in the phase 1a trial of ABI-6250, its hepatitis delta virus entry inhibitor candidate. The study aims to evaluate the safety, tolerability and pharmacokinetics of the therapy across single and multiple ascending...
AST SpaceMobile Wins New $43 Million Contract to Continue Work on Space Communications Network; Shares Climb
AST SpaceMobile Wins New $43 Million Contract to Continue Work on Space Communications Network; Shares Climb
Feb 26, 2025
10:20 AM EST, 02/26/2025 (MT Newswires) -- AST SpaceMobile ( ASTS ) said Wednesday it has won a new contract award from the US Space Development Agency valued at around $43 million to continue work on a space-based cellular communications network in low-Earth orbit. The new contract builds on a preliminary contract award disclosed by AST SpaceMobile ( ASTS )...
DMY Squared Technology, Horizon Quantum Sign Business Combination Deal
DMY Squared Technology, Horizon Quantum Sign Business Combination Deal
Feb 26, 2025
10:26 AM EST, 02/26/2025 (MT Newswires) -- DMY Squared Technology Group ( DMYY ) and Horizon Quantum Computing said Wednesday they have signed a non-binding letter of intent for a business combination. Under the terms, the pre-money equity value of Horizon Quantum is roughly $500 million, the companies said, adding that they intend to execute an agreement in Q2 and...
EU approves $2.3 billion takeover of Infinera by Nokia
EU approves $2.3 billion takeover of Infinera by Nokia
Feb 26, 2025
BRUSSELS (Reuters) - The EU Commission on Wednesday said it had unconditionally approved the $2.3 billion acquisition of U.S. optical semiconductors and networking equipment maker Infinera ( INFN ) by Nokia. The commission said the takeover raised no concerns, as the companies' combined market share in the supply of optical transport equipment would be moderate and would still face credible...
Copyright 2023-2026 - www.financetom.com All Rights Reserved